Silence Therapeutics: PV Readouts Could Reprice the Story - Initiating Buy
Silence (SLN) trades at a market cap of ~$429M and is a candidate for a meaningful re-rating if upcoming polycythemia vera (PV) data and continued RNA-platform progress validate the program. We initiate a long trade with a clear entry, stop and a long-term target that still sits well below many analyst 12-month averages.